{"version":"1.0","provider_name":"Times South Africa","provider_url":"https:\/\/timessouthafrica.com","author_name":"TSA","author_url":"https:\/\/timessouthafrica.com\/author\/tsa\/","title":"Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology - Times South Africa","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"fwqyr4VbYt\"><a href=\"https:\/\/timessouthafrica.com\/zenas-biopharma-announces-publication-of-phase-2-study-of-obexelimab-an-investigational-treatment-for-igg4-related-disease-igg4-rd-in-the-lancet-rheumatology\/\">Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/timessouthafrica.com\/zenas-biopharma-announces-publication-of-phase-2-study-of-obexelimab-an-investigational-treatment-for-igg4-related-disease-igg4-rd-in-the-lancet-rheumatology\/embed\/#?secret=fwqyr4VbYt\" width=\"600\" height=\"338\" title=\"&#8220;Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology&#8221; &#8212; Times South Africa\" data-secret=\"fwqyr4VbYt\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions WALTHAM, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) \u2014 Zenas BioPharma, a global biopharmaceutical company committed to [\u2026]","thumbnail_url":"https:\/\/ci4.googleusercontent.com\/proxy\/uKB53apOGpq1uBFr3jL2xq7DljBlDizA8kP_bse9zMswtryZwUpX2l8-dBVZjbMcy4BP6eye74dY1mveMGaDhMjrBaEvTRVMj0LAdofMpe__k82xXJe3aXTB34HGxufcwU1IscsZGDPJvoboHBXIfm0E1QZAn7guf8S82tZ54J9VrZkJqXF7XhpOl3MHdGK_XJ_Zjw=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWI5YjA3YTAtZmViOC00YTczLTgyMDAtYThiMWQ3Mjk4OGI4LTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png"}